

Redeye Initiates Coverage of Neola Medical

Redeye initiates coverage of Neola Medical, a Swedish medtech company specialising in neonatal intensive care. We argue its flagship product, Neola, fills an unmet need for the continuous lung monitoring of preterm born infants, and we expect a significant sales take-off following its US launch in 2026e. Our fair value range suggests a c30% upside potential in the share, and we identify key catalysts in upcoming clinical data and soon-to-be-initiated regulatory processes.

[Read more and download the Research Report.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Redeye Initiates Coverage of Neola Medical](#)